LHW090-A7
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
LHW090-A7 is a potential inhibitor of neutral endopeptidase (NEP). It has been shown that the NEP inhibitors induced the increase of plasma levels of endogenous atrial natriuretic peptides (NPs), which makes the inhibition of NEP to be a potential novel therapeutic approach.
NPs block the activity of the renin-angiotensin-aldosterone system, have antihypertrophic and antiproliferative effects, and reduce sympathetic drive. Additionally, NEP inhibitors are expected to trigger natriuretic and diuretic effects. NEP, a zinc-dependent, membrane-bound endopeptidase, hydrolyses peptides on the amino side of hydrophobic residues. It is essential for the processing and catabolism of vasoactive peptides as well as peptides involved in natriuresis and diuresis. NEP is indirectly and directly involved in the regulation of signaling pathways. NEP is implicated in proteolytic degradation or activation of bioactive peptides, growth factors, and cytokines in an indirect fashion. In addition to this, NEP is involved in regulating signaling pathways in a direct manner [1].
In vitro: Up to now, in vitro study of LHW090-A7 is still in the development stage.
In vivo: Up to now, in vivo study of LHW090-A7 is still in the development stage.
Reference:
[1]. Mangiafico, S., Costello-Boerrigter, L., Andersen, I., Cataliotti, A., & Burnett, J. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal. 2012;34(12): 886-893.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 397.8 |
Formula | C20H21ClNO4·Na |
Solubility | ≤1mg/ml in DMSO;5mg/ml in dimethyl formamide |
Chemical Name | (αS)-3'-chloro-α-[[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]-[1,1'-biphenyl]-4-propanoic acid, monosodium salt |
SDF | Download SDF |
Canonical SMILES | ClC1=CC=CC(C2=CC=C(C[C@H](N[C@H](C(OCC)=O)C)C([O-])=O)C=C2)=C1.[Na+] |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |